Abstract: A method of restoring the balance of osteoclast to osteoblast activity in a patient having rheumatoid arthritis comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. A method for treating arthritis-induced bone erosion in a patient comprising administering to a patient a therapeutically effective amount of the compound N-(3,4-dichlorophenyl)-N-methylpropanamide is provided. The compound N-(3,4-dichlorophenyl)-N-methylpropanamide is administered in a pharmaceutically acceptable composition to said patient. A mode of action of N-(3,4-dichlorophenyl)-N-methyl propanamide comprising targeting transient receptor potential channels is provided.

Abstract: This invention provides a composition comprising Formula I, or salt thereof, wherein X is chlorine, Y is a methyl group, and R is an alkyl group having a carbon chain length of three carbon atoms. A method of inhibiting osteoclast development and a method for preventing bone erosion in a patient using the compositions of Formula I are disclosed.

Abstract: This invention provides a composition comprising Formula I, or salt thereof, wherein X is chlorine, Y is a methyl group, and R is an alkyl group having a carbon chain length of three carbon atoms. A method of inhibiting osteoclast development and a method for preventing bone erosion in a patient using the compositions of Formula I are disclosed.

Abstract: This invention provides a composition comprising Formula I, or salt thereof, wherein X is either chlorine or bromine, Y is either hydrogen or an alkyl group having a carbon chain length from 1 to 5 carbon atoms, and R is an alkyl group having a carbon chain length from 1 to 5 carbon atoms, except that X is not chlorine when Y is hydrogen and R is an ethyl group. A method of preventing bone erosion in a patient and a method of reducing inflammation in a patient using the compositions of Formula I are disclosed.

Abstract: The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.

Abstract: The invention discloses compositions and methods for decreasing osteoclast which are useful for the treatment of a variety of bone loss disorders.

Abstract: The present invention provides an inhibitor of osteoblastic stem cell factor binding and/or activity, for example, an antibody or an antisense oligonucleotide. Also provided are pharmaceutical compositions comprising these inhibitors of osteoblastic stem cell factor binding and/or activity. Further provided is a method of regulating the activity of osteoclasts, comprising the step of: inhibiting the binding and/or activity of osteoblastic stem cell factor.

Abstract: The present invention provides a method for blocking a cellular proton pump that comprises contacting a cell with a cellular proton pump-blocking effective quantity of In-EDTA or Tl-EDTA. The present invention also provides a method of treating or preventing cell-mediated disorders in a vertebrate animal by administering In-EDTA or Tl-EDTA to the vertebrate animal, as well as a method for stopping the cellular proton pump-blocking effect of Group IIIa metals such as Ga, In, and Tl, through use of suitable chelating agents. Suitable compositions for use in the aforementioned methods are provided as well.

Abstract: The present invention provides a method for blocking a cellular proton pump that comprises contacting a cell with a cellular proton pump-blocking effective quantity of In-EDTA or Tl-EDTA. The present invention also provides a method of treating or preventing cell-mediated disorders in a vertebrate animal by administering In-EDTA or Tl-EDTA to the vertebrate animal, as well as a method for stopping the cellular proton pump-blocking effect of Group IIIa metals such as Ga, In, and Tl, through use of suitable chelating agents. Suitable compositions for use in the aforementioned methods are provided as well.

Abstract: Disclosed are methods and compositions for use in inhibiting osteoclast activity and, particularly, the osteoclast acid secretion that leads to bone-degradation. It is shown that the isoflavone genistein inhibits the acid secretion of osteoclasts and reduces bone resorption. The present invention thus provides advantageous methods for use in inhibiting osteoclast activity, as may be employed to reduce bone loss, for example, in patients with osteoporosis, metastatic bone cancers and renal failure.